Kymera Therapeutics, Inc.
KYMR
$43.87
$2.054.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -82.15% | -35.06% | -392.43% | -18.20% | -8.41% |
| Total Depreciation and Amortization | 7.53% | 40.18% | 123.01% | 122.01% | 115.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.83% | -15.29% | 9.38% | 8.08% | 5.71% |
| Change in Net Operating Assets | 110.29% | -332.63% | -129.86% | -109.82% | -84.44% |
| Cash from Operations | -39.47% | -99.92% | -867.98% | -58.59% | -21.78% |
| Capital Expenditure | 85.18% | 93.69% | 91.95% | 102.34% | 56.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 198.64% | 115.19% | 127.31% | -330.17% | -56.38% |
| Cash from Investing | 283.72% | 114.70% | 261.80% | -360.58% | -56.35% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.52% | 4.48% | -131.68% | -88.53% | -5.39% |
| Issuance of Common Stock | 13,851.70% | -99.85% | 3,014.07% | 187,630.60% | 7.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 17,302.69% | -99.93% | 42.97% | 121,904.85% | 8.20% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,049.94% | -84.14% | -66.99% | 50.21% | -1,470.87% |